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Challenges in Clinicogenetic Correlations:
One Gene – Many Phenotypes
Francesca Magrinelli, MD,1,2,* Bettina Balint, MD,1,3 and Kailash P. Bhatia, MD, FRCP1,*
ABSTRACT: Background: Progress in genetics – particularly the advent of next-generation sequencing
(NGS) – has enabled an unparalleled gene discovery and revealed unmatched complexity of genotype–
phenotype correlations in movement disorders. Among other things, it has emerged that mutations in one
and the same gene can cause multiple, often markedly different phenotypes. Consequently, movement
disorder specialists have increasingly experienced challenges in clinicogenetic correlations.
Objectives: To deconstruct biological phenomena and mechanistic bases of phenotypic heterogeneity in
monogenic movement disorders and neurodegenerative diseases. To discuss the evolving role of movement
disorder specialists in reshaping disease phenotypes in the NGS era.
Methods: This scoping review details phenomena contributing to phenotypic heterogeneity and their underlying
mechanisms.
Results: Three phenomena contribute to phenotypic heterogeneity, namely incomplete penetrance, variable
expressivity and pleiotropy. Their underlying mechanisms, which are often shared across phenomena and non-
mutually exclusive, are not fully elucidated. They involve genetic factors (ie, different mutation types, dynamic
mutations, somatic mosaicism, intragenic intra- and inter-allelic interactions, modifiers and epistatic genes,
mitochondrial heteroplasmy), epigenetic factors (ie, genomic imprinting, X-chromosome inactivation,
modulation of genetic and chromosomal defects), and environmental factors.
Conclusion: Movement disorders is unique in its relianceon clinical judgment to accurately definediseasephenotypes.
This hasbeen reaffirmedby theNGS revolution, which provides ever-growing sequencingdata and fuels challenges in
variant pathogenicity assertions for suchclinically heterogeneousdisorders. Deepphenotyping,with characterization and
continual updatingof “core”phenotypes, andcomprehension of determinants of genotype–phenotypecomplex
relationships are crucial for clinicogenetic correlations andhave implications for the diagnosis, treatment andcounseling.
“Phenotype” is the observable or quantifiable characteristics of
an individual – including findings of nongenetic investigations –
which result from the interaction of its gene makeup with envi-
ronmental factors. However, in a narrower sense, geneticists refer
to phenotype as the set of specific features arising from the
expression of one or few genes. In keeping with this, “genotype”
is the genetic constitution of an individual, overall or at a specific
locus, that is responsible of a given phenotype.1
The identification of the first disease genes in the early 1980s
suggested simplistically that phenotypes could be precisely predicted
if genotypes were determined, therefore enabling consistent
genotype–phenotype correlations.2 However, advances in genetics
– particularly the advent of next-generation sequencing (NGS) –
have revealed that the relationship between genotype and pheno-
type is not straightforward, even for single-gene disorders.1,2 This
has become more evident with the use of hypothesis-free whole-
exome (WES) and whole-genome sequencing (WGS) instead of
candidate gene approaches to identify new disease genes.2,3
Movement disorders (MD) is relatively unique among neurol-
ogy subspecialities in its reliance on clinical assessment as well as
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clinicians’ expertise and experience to accurately define disease
phenotypes.4 Indeed, MD are highly heterogeneous conditions,
often present as complex clinical pictures with overlapping mani-
festations, and almost invariably lack of diagnostic biomarkers.4
Equally, progress in genetics has enabled an unparalleled gene dis-
covery and revealed unmatched complexity of genotype–
phenotype associations in the field of MD.5 Consequently, MD
specialists have increasingly faced challenges in clinicogenetic cor-
relations, with implications for diagnosis, treatment and genetic
counseling.
Mutations in different genes may account for the same “core”
phenotype (genetic heterogeneity). For instance, variants in
NKX2-1, ADCY5 and PDE10A can all manifest with early-onset
chorea,6 mutations in PRRT2, MR-1, SCN8A and SLC16A2 with
paroxysmal kinesigenic dyskinesia,7 and defects in GLRA1, GLRB
and SLC6A5 with hyperekplexia.8 On the other hand, mutations
in one and the same gene can cause multiple, often markedly differ-
ent phenotypes (phenotypic heterogeneity), which is the topic of
this article.
Three main phenomena contribute to phenotypic heterogeneity
of monogenic disorders (Fig. 1). First, some individuals carrying a
disease-causing mutation in a gene may not express the corresponding
disease phenotype, which is defined “incomplete penetrance”.1,9,10
Second, if the mutation is expressed, the disease phenotype can pre-
sent with varying degrees of severity across carriers, therefore showing
“variable expressivity”.1, 10 Finally, a mutation in a gene controlling
two or more phenotypic traits may account for multiple, apparently
unrelated, disease phenotypes as a result of “pleiotropy”.1,11 Although
being distinct concepts, penetrance, expressivity and pleiotropy are
inter-related and often underpinned by shared biomechanisms involv-
ing genetic, epigenetic and environmental factors. Stochastic (ie, ran-
dom) events, which can occur at either the DNA, RNA, or protein
level, might also play a role in phenotypic heterogeneity, but their
relative contribution is hardly quantifiable (Fig. 2).12
This review deconstructs the “One Gene – Many Pheno-
types” paradigm providing examples of monogenic MD and
neurodegenerative diseases. We analyze phenomena contributing
to phenotypic heterogeneity and underlying genetic and non-
genetic factors. We also discuss the evolving role of MD special-




“Penetrance” of a monogenic disorder is the conditional probabil-
ity that an individual carrying a mutation at the corresponding
gene manifests the disease phenotype. If this probability does not
equal 100% within a specific time period, the disorder displays
“incomplete penetrance” (Fig. 1).1,9,10 We favor this expression
over “reduced penetrance” since the latter gives more room to the
currently evolving concept of nuances of expressivity rather than
the all-or-none issue of the disease phenotype being manifested or
not. Non-penetrance can be regarded as an extreme endpoint of
phenotypic heterogeneity.
FIG. 1. Phenomena contributing to phenotypic heterogeneity in monogenic disorders. Left and middle boxes. Squares represent
individuals carrying the same variant in a gene. Left box. Shaded square means the individual manifests the disease phenotype. Non-
shaded square means the individual does not manifest the disease phenotype (non-penetrance). Middle box. Shaded square means the
individual manifests the disease phenotype with different degree of severity. Non-penetrance (non-shaded squares) can be viewed as an
extreme endpoint of variable expressivity. Right box. Individual carrying a variant in a pleiotropic gene with multisystemic effects. In the
example, a variant in the NKX2-1 gene encoding the thyroid transcription factor 1, with involvement (shaded squares) of the nervous
system (chorea, choreoathetosis), pituitary gland (cystic mass), thyroid (congenital hypothyroidism), lung (neonatal respiratory distress,
chronic interstitial lung diseases), and urinary system (megabladder).
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Incomplete penetrance is most evident in autosomal dominant
(AD) disorders, which, by definition, are manifested in heterozygotes
and might therefore be expected to have full penetrance in carriers
of a pathogenic variant.1 Hence, some AD disorders occasionally
appear to “skip” a generation, meaning that individuals carrying an
inherited or de novo mutation do not express the disease phenotype
(asymptomatic carriers) but can transmit the mutant allele to the off-
spring.1 This occurrence, which is well-described for example in
TOR1A-related dystonia (DYT-TOR1A; OMIM# 128100),13–15
SGCE-related myoclonus-dystonia (OMIM# 159900),16–18 and
many repeat expansion disorders,19 poses a challenge in defining the
inheritance pattern, especially in small pedigrees.
Autosomal recessive (AR), X-linked and mitochondrial disor-
ders can also exhibit incomplete penetrance. In Wilson’s disease
(WD; OMIM# 277900), a discrepancy between the frequency
of individuals carrying biallelic pathogenic variants in ATP7B
(1:7000)20 and the prevalence determined by mass screening
using ceruloplasmin in blood/urine (1–2:3000)21,22 suggests the
penetrance is not full, particularly for variants mapping outside a
three-exon hotspot gene region where 50% of WD-causing
mutations were identified in a UK population study.23 Pene-
trance is incomplete in females with premutation and mutation
in FMR1 causing X-linked dominant fragile X-associated
tremor-ataxia syndrome (FXTAS; OMIM# 300623) and fragile
X syndrome (FXS; OMIM# 300624), respectively.24 Finally,
disorders due to mutations in mitochondrial DNA (mtDNA)
show incomplete penetrance25 either because the ratio between
mutated and wild-type mtDNA does not reach the “phenotypic
threshold level” or despite the mutation being present in all
mtDNA copies.26,27
Among others, age, gender and ethnicity are drivers of incom-
plete penetrance in certain diseases.
Age-Related Penetrance
Some monogenic disorders show late age of onset, with penetrance
being very low in the first decades and increasing with age. Different
mechanisms account for the slow development of adult-onset neu-
rogenetic disorders. For instance, mutant gene products or substrates
of defective enzymes may accumulate slowly, and/or the pathogen-
esis involve a gradual process of neuronal loss requiring time before
the number of surviving cells drops below a critical threshold or, at
least theoretically, overcomes brain plasticity, finally causing symp-
tom onset. This is exemplified by repeat expansion disorders,19 such
as Huntington disease (HD; OMIM# 143100) and FXTAS, in
which mutant alleles with “intermediate” number of repeats are
often associated with incomplete penetrance and late presentation.
Furthermore, the estimate prevalence of LRRK2-related Parkinson’s
disease (PD; OMIM# 607060) among non-Ashkenazi Jewish car-
riers of the monoallelic variant NM_198578.4:c.6055G>A (p.
Gly2019Ser) was found to be 7.33% at 60 years, 29.17% at 70 years,
and 42.52% at 80 years.28
FIG. 2. Overview of genetic and nongenetic (epigenetic, environmental) factors underpinning incomplete penetrance, variable expressivity
and pleiotropy of mutant allele(s). Stochastic (ie, random) events might act at all levels and further contribute to phenotypic
heterogeneity.
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Gender-Related Penetrance
The effect of gender on penetrance has been observed in some
single-gene disorders. For instance, GCH1-associated dopa-
responsive dystonia (OMIM# 128230) shows a 2.3 times higher
mutation prevalence in females than males.29 Mechanisms under-
lying female predominance are not understood, although sexual
differentiation of mesencephalic dopaminergic neurons and sex
hormones might be contributors to gender-related vulnerability
to tetrahydrobiopterin deficiency.29
Ethnicity-Related Penetrance
Penetrance may be influenced by ethnicity, as demonstrated in
LRRK2-PD, in which age-related penetrance of the p.Gly2019-
Ser variant was found to significantly differ between Tunisian
Arab-Berbers and Norwegians, the former having a median age
at onset 10 years earlier than the latter.30 Moreover, in ATXN3-
related spinocerebellar ataxia (formerly SCA3; OMIM# 109150)
Asians have a mean age of onset 4.75 years and 6.64 years higher
than Caucasians and African Americans, respectively.31
In many cases determinants of incomplete penetrance are
unknown. These might include the interaction among multiple
factors, small or large effect size, etc., but any consideration in
this regard is purely speculative.
Variable Expressivity
“Expressivity” is the extent to which a given genotype is expressed
at the phenotypic level. When the same genetic variant is
expressed and shows quantitatively different effects among distinct
individuals, even among members of the same family (intrafamilial
variability), the corresponding disease phenotype displays “variable
expressivity” (Fig. 1).1,10 Variable expressivity is recognized in
monogenic disorders with all patterns of inheritance and represents
a major contributor to phenotypic heterogeneity.
Several underpinnings of variable expressivity have been pro-
posed so far and partly overlap with those of incomplete pene-
trance. For instance, variable expressivity can correlate with the
repeat size (ie, length of the expansion) in repeat expansion dis-
orders10 or with different mutation types in the same gene, with
missense, nonsense and frameshift variants resulting in partially
functional or non-functional gene products. Nuances of expres-
sivity may also be related to tissue-dependent thresholds of sus-
ceptibility to the same genetic defect; namely, tissues where a
given mutation is actually expressed can differ in the level of pro-
tein deficiency at which symptoms manifest (with different
degree of severity). Furthermore, in mitochondrial disorders, var-
iable expressivity can depend on different suprathreshold degrees
of heteroplasmy of mutant mtDNA. Finally, inter-individual var-
iable expressivity may reflect differences in the allelic constitution
of the rest of the genome or the interplay between (epi)genetic
and environmental factors.
Overall, variable expressivity stands among the most challenging
hindrances in the interpretation of genetic variants. In many cases,
such as in ATP1A3- and TUBB4-related disorders,32,33 it remains
controversial whether phenotypic heterogeneity is due to variable
expressivity (ie, phenotypic spectrum of the same disease), pleiot-
ropy (ie, discrete phenotypes related to the involvement of differ-
ent organs or different neuronal subpopulations in exclusively
neurological disorders), or both.34 Elucidating the molecular basis
of variable expressivity, for example by implementing functional
studies on the effect of different variants in the same gene, may be
crucial in genotype–phenotype correlations.
Pleiotropy of Mutant Allele(s)
“Pleiotropy” is the phenomenon whereby a single gene influ-
ences two or more distinct phenotypic traits.1,11 Germline muta-
tions in pleiotropic genes account for disease phenotypes
showing selective involvement of a subset of tissues, organs or
systems which constitutionally express those genes (Fig. 1). This
occurs because all cells are structurally and functionally special-
ized through diverse gene transcriptional profiles despite con-
taining an identical genome except for postzygotic (somatic)
mutations11; namely, under physiological conditions, cells only
express a fraction of genes required for their baseline (“house-
keeping” genes) and specific (“luxury” genes) structure and func-
tions. Notwithstanding, individuals carrying mutations in a
pleiotropic gene may present with high-level phenotypic hetero-
geneity due to the qualitatively (eg, different organs/systems
affected) and quantitatively (ie, severity) wide spectrum of mul-
tisystemic involvement.
Pleiotropy has initially been described in monogenic disorders.
In this case, mutations in genes that are expressed by different cell
types cause a constellation of apparently unrelated clinical features
secondary to multiorgan/multisystemic dysfunctions. However,
pleiotropy has revealed itself as a more widespread phenomenon
occurring also for small-size effect variants. A review of genome-
wide association studies revealed that 17% of genes and 4%–5%
of genetic variants are pleiotropic, and this is often observed in
neurological disorders.11 Despite its frequency and contribution to
phenotypic heterogeneity, little is known about mechanisms
underlying pleiotropy, as well as about properties of pleiotropic
proteins. A pleiotropic mutation can account for a multisystemic
disorder in various ways.35 Among others, the resulting gene prod-
uct can be used for the same biochemical purpose in multiple bio-
logical pathways. The mutant protein can also have more than one
function through different domains or interaction with different
partners in different cell types. Moreover, the defective gene prod-
uct may affect a singular molecular function, whose alteration sec-
ondarily impacts on other functions with a cascade mechanism.35
Analysis of multisystemic disorders in humans has shown that plei-
otropy is more common in genes encoding essential proteins and
“hub” proteins (proteins with multiple interactors),11 thus con-
firming the need to study interactome networks to further progress
in our understanding of genetic diseases.36
Examples of genes encoding pleiotropic proteins are VCP and
NKX2-1.37,38 VCP encodes the valosin-containing protein, a
ubiquitously expressed protein involved in several cellular activi-
ties, including cell cycle control, membrane fusion and the
ubiquitin-proteasome degradation pathway.34 Pathogenic variants
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in VCP account for a rare AD multisystemic disorder characterized
by inclusion body myopathy, Paget disease of bone and
frontotemporal dementia (OMIM# 605382).37 They have also
been linked to amyotrophic lateral sclerosis (OMIM# 613954)39
and Charcot–Marie–Tooth disease type 2Y (OMIM# 616687).40
NKX2-1 codes for the thyroid transcription factor 1, a nuclear
protein expressed during early development of the forebrain
(especially basal ganglia and hypothalamus), lung, and thyroid.35
Heterozygous pathogenic variants in NKX2-1 have been linked
to the brain-lung-thyroid syndrome (OMIM# 610978), a multi-
organ disorder characterized by early-onset chorea, respiratory
distress syndrome, and congenital hypothyroidism.38 Dysfunc-
tions of the pituitary gland and urinary system (pyelectasis and
megabladder) can be associated with mutations in NKX2-1
(Fig. 1).41,42
Pleiotropic genes represent a major challenge when analyzing
and prioritizing genes and genetic variants for their potential
association with disease phenotypes.
Mechanisms underlying
phenotypic heterogeneity
Genetic, epigenetic and environmental factors may influence
penetrance, expressivity and pleiotropy of mutant alleles in a
non-mutually exclusive manner, even in monogenic disorders,
whose phenotype, by definition, is largely determined by the
genotypic status at just one locus (Fig. 2). In many cases, the




Different mutation types in one and the same gene may either
cause variable expressivity (ie, mild or severe forms of the same
disease phenotype), or account for rather different disorders, thus
representing a molecular explanation for pleiotropy.
A subset of genes is highly dosage sensitive, meaning that
changes in a gene dose and consequently in the amount of gene
product are critically relevant. Changes in gene copy number
(copy number variations) may account for disease by modifying
the amount of protein product beyond normal limits.43,44 Further-
more, certain point mutations have the same effect by reducing
(loss-of-function) or amplifying (gain-of-function) gene expres-
sion. To oversimplify, disease-causing missense mutations may
result in gene products that still retain their function to some
extent (partially functional proteins). On the contrary, nonsense
and frameshift mutations lead to transcripts carrying a premature
termination codon which are often subject to nonsense-mediated
mRNA decay,45 thus resulting in loss-of-function alleles, or can
rarely escape depletion and be translated to truncated proteins with
potential gain-of-function and/or toxic effects. However, the
impact of a variant also depends on its location within the protein
(eg, inside/outside functional domains, in sites that are critical for
its tertiary and quaternary structures). For instance, missense muta-
tions involving the catalytic site of an enzyme can have highly det-
rimental consequences. Phenotypic heterogeneity depending on
different mutation types is exemplified by enzyme deficiency dis-
orders, in which there is often a good correlation between gene
product levels and phenotype severity. For example, the pheno-
typic spectrum related to the X-linked gene HPRT1 reflects quite
predictably the residual activity of the enzyme hypoxanthine gua-
nine phosphoribosyltransferase 1, which is involved in the synthe-
sis of purine nucleotides through the purine salvage pathway.46
Loss-of-function mutations lowering the normal enzymatic activ-
ity <60% result in asymptomatic hyperuricemia or gout (OMIM#
300323), whereas neurological features appear when HPRT1
activity drops below 8%. With HPRT1 activity 1.5% individuals
manifest Lesch–Nyhan syndrome (OMIM# 300322) but can still
have normal intelligence. A decrease in HPRT activity to <1.4%
results in full Lesch–Nyhan syndrome, including choreoathetosis,
pyramidal signs, self-injurious behavior, and intellectual disability.1
Another example is glucose transporter type 1 (Glut1) deficiency
syndrome, which is caused by heterozygous or, less frequently,
biallelic mutations in the SLC2A1 gene and has a wide phenotypic
spectrum.7,47 The classic phenotype (OMIM# 606777) is character-
ized by early-onset chronic encephalopathy with pharmacoresistant
epilepsy, acquired microcephaly, spasticity and MD. Milder pheno-
types may manifest during childhood or adulthood with epilepsy,
cognitive/behavioral issues and MD (most frequently paroxysmal
exercise-induced dyskinesia, but also ataxia), either isolated or in var-
ious combinations.47 A correlation between the specific type of
SLC2A1 pathogenic variant and the clinical severity has been
observed.47,48 Missense variants are found predominantly in milder
phenotypes, possibly reflecting the presence of a partially functional
Glut1 in the brain.47,48 On the contrary, splice site, nonsense and
frameshift mutations as well as exon and complete gene deletions
occur almost only in the classic severe phenotype.47,48
Among gain-of-function mutations, multiplications in the
α-synuclein gene (SNCA) account for AD parkinsonism, auto-
nomic dysfunction and dementia with a gene dosage effect.49–52
The clinical phenotype related to whole-gene duplication (ie,
one extra copy of wild-type SNCA) resembles idiopathic PD,
whereas triplication and quadruplication (ie, two and three extra
copies, respectively) cause increasingly severe phenotypes of
early-onset rapidly progressive PD with dysautonomia and cog-
nitive impairment.49–52
Different types of monoallelic mutations in CACNA1A,
which encodes the voltage-gated P/Q-type calcium channel
subunit alpha-1A, are associated with a number of different phe-
notypes, including SCA6 (OMIM# 183086),53 episodic ataxia
type 2 (EA2; OMIM# 108500),54 familial hemiplegic migraine
type 1 (FHM1; OMIM# 141500)55 with or without progressive
cerebellar ataxia, benign paroxysmal torticollis of the infancy,56
early infantile epileptic encephalopathy,57 and paroxysmal head
tremor.58 Of the first three allelic disorders reported, SCA6 is a
polyglutamine disorder caused by a 20-to-33 CAG triplet expan-
sion in exon 47 of CACNA1A,53 whereas EA2 and FHM1 are
due to CACNA1A loss-of-function mutations and gain-of-
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function missense mutations, respectively.54,55 CACNA1A-
related disease phenotypes described more recently have revealed
that there is a wide phenotypic overlap between hemiplegic
migraine, diverse forms of cerebellar dysfunction and epilepsy,
and that genotype–phenotype correlation might be not as strict
as initially reported. For example, both loss-of-function and
gain-of-function CACNA1A mutations cause severe develop-
mental epileptic encephalopathies in the spectrum of Lennox–
Gastaut syndrome and congenital ataxia.57
Dynamic Mutations
Oligonucleotide repeat expansions are unstable (“dynamic”)
mutations whose repeat size can change after DNA replication
(Fig 3A).59 They account for more than 40 neurological disor-
ders, including HD (CAG repeat expansion in HTT), FXTAS
and FXS (CGG repeat expansion in FMR1), dentatorubral-
pallidoluysian atrophy (DRPLA; OMIM# 125370; CAG in
ATN1), C9orf72-related disorders (GGGGCC in C9orf72) and
some SCA.19 However, the number of repeat expansion disor-
ders is set to rise with the advent of long-read sequencing and
other technologies.60 Repeat instability can influence penetrance
and expressivity, leading to intrafamilial intergenerational pheno-
typic heterogeneity. It may also occur within specific tissues and
contribute to pleiotropy. Since repeat size correlates inversely
with age of onset and phenotype severity in many repeat expan-
sion disorders, repeat instability provides a molecular explanation
for genetic anticipation.19
Repeat instability occurs during parent-to-offspring transmis-
sion (germline instability), with parent-of-origin biases possibly
due to specific processes occurring during spermatogenesis or
oocytogenesis. For example, paternal expansion bias is observed
in HD and DRPLA, whereas paternal contraction and maternal
expansion biases (modulated by epigenetics factors) are observed
in FXTAS and FXS.59
Some repeat expansion disorders also exhibit tissue-specific
somatic repeat instability whose timing, pattern and tropism dif-
fer among disorders.59 For instance, it occurs throughout the life-
time for HD and DRPLA, while it occurs only in fetal tissues for
FXS and FXTAS. The contribution of brain-specific somatic
repeat instability to the progression rate of neurodegenerative
repeat expansion disorders is far from being clarified.59
Somatic Mosaicism
De novo pathogenic mutations can occur during gametogenesis,
thus resulting in the presence of gametes with mutant alleles in
otherwise healthy individuals (germline mosaicism, Fig 3B) and
the transmission of the mutant alleles to the zygote.61 However,
most mutations occur in cells at any time in postzygotic life due
to endogenous errors in DNA replication and repair. As a result
of postzygotic mutations, individuals are mosaic with genetically
distinct cell populations characterized by different mutational
load (somatic mosaicism, Fig 3C).62 Somatic mosaicism contrib-
utes to variable expressivity of single-gene disorders through
gene dose effect or by acting in addition with other genetic or
epigenetic factors.62 It has been reported in individuals with no-
penetrance or mild presentation of Mendelian disorders, includ-
ing AD ADCY5-related early-onset chorea (OMIM# 606703).
Low-level and tissue-limited mosaicism represent major chal-
lenges for clinicogenetic diagnoses.63 NGS with deep sequence
coverage and DNA extraction from tissues of interest enhance
sensitivity and enable accurate quantification of the degree of
somatic mosaicism.61,64
Intragenic Intra- and Inter-Allelic
Interactions
Phenotypic heterogeneity may depend on intragenic interactions
within the same allele (cis-regulation, Fig 3D) or between the
two alleles (trans-regulation, Fig 3E). Prion diseases offer an
example of intragenic intra-allelic interaction.65 The missense
mutation NM_000311.5:c.532G>A (p.Asp178Asn) in the prion
protein gene (PRNP) results in two different phenotypes, either
familial Creutzfeldt-Jacob disease (fCJD; OMIM# 123400) or
fatal familial insomnia (FFI; OMIM# 600072), depending on
whether the PRNP cis codon 129 is methionine or valine, with
the former typically associated with FFI and the latter with
fCJD.65
An intragenic inter-allelic interaction influences disease pene-
trance in DYT-TOR1A.13 DYT-TOR1A is almost invariably
due to the heterozygous in-frame deletion NM_000113.2:
c.907_909delGAG (p.Glu303del) in the gene encoding the
ATP-binding protein torsinA.13 The penetrance of this variant is
30%.66 The presence of the polymorphism NM_000113.2:
c.646G>C (p.Asp216His) in trans configuration with the GAG
deletion in TOR1A reduces the penetrance to 3%.14
Furthermore, a significant intragenic inter-allelic interaction
between the non-expanded (wild-type) allele in trans and age at
onset was observed in individuals with SCA1 (OMIM# 164400),
SCA6 and SCA7 (OMIM# 164500). “Intermediate” wild-type
alleles interacting with the expanded allele decrease age at onset in
SCA1 and SCA6, whereas short or medium wild-type alleles
interacting with the expanded allele decrease age at onset in
SCA7.67
Intergenic Interactions (Modifier Genes
and Epistasis)
Modifier and epistatic genes modulate the expression of a target
disease gene by interacting from a distance with its locus with
different levels of complexity (Fig 3F).68–70 Modifiers genes
influence penetrance, expressivity, and pleiotropy of a mutant
allele through simple, additive interactions with the target gene.
By contrast, the crosstalk between the target disease gene and
epistatic genes results in multiplicative (ie, non-additive) effects
which are more difficult to explore, such as masking the disease
phenotype or expressing a new disease phenotype.
Different alleles at a modifier locus can have protective effects,
resulting in late-onset and/or milder disease phenotypes, or
aggravating effects, by inducing young-onset and/or severe
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phenotypes.68 For example, although individuals with HD carry
the same type mutation (ie, CAG repeat expansion) in HTT, it is
unlikely that two affected with exactly the same HTT CAG
repeat size exhibit the same phenotype in terms of age of onset
and clinical manifestations.71 The presence and size of an
expanded CAG tract contributes only 60% on average to indi-
vidual variation in HD age of onset, thus suggesting the presence
of other (epi)genetic and environmental determinants. Age of
onset in individuals with HD was found to be modulated by
CAG repeat sizes in the normal range of ATXN3, CACNA1A
and the androgen receptor gene.71
Another example comes from some SCAs, whose age at onset
is influenced by other genes containing CAG repeats, namely
ATXN7 in SCA2 (OMIM# 183090), ATXN2, ATN1 and HTT
in SCA3, ATXN1 and ATXN3 in SCA6, and ATXN3 and TBP
in SCA7.67
Recently, in the TOR1A-dystonia mouse model, reduced
expression of torsinB encoded by the paralog TOR1B was found
to cause a dose-dependent worsening of twisting, whereas tor-
sinB overexpression was proven to rescue torsinA deficiency.72
These findings identify torsinB as a potent modifier of torsinA
loss-of-function phenotypes and suggest that enhancing neuronal
torsinB expression in neurons at the appropriate developmental
stage might represent a promising disease-modifying strategy.72
Mitochondrial Inheritance
Disease phenotypes resulting from (predominantly) maternally
inherited mutations in mtDNA are highly heterogeneous in
terms of penetrance, expressivity and pleiotropy due to heter-
oplasmy, which is secondary to random segregation of mito-
chondria during cell replication (Fig 3G).25 Mature oocytes
typically contain more than 100,000 mtDNA copies.1 If they
carry a variant in at least one copy of mtDNA, any postzygotic
cell can be homoplasmic for the wild-type (ie, all mtDNA copies
are wild-type), homoplasmic for the mutant (ie, all mtDNA cop-
ies carry the mutation), or heteroplasmic (ie, wild-type and
mutant mtDNA molecules are present). Every child of an
affected heteroplasmic mother inherits at least some mutant
mtDNA copies whose proportion is difficult to predict.
FIG. 3. Schematic of genetic and epigenetic mechanisms underlying phenotypic heterogeneity. (A) Germline instability of a CAG triplet
repeat expansion (dynamic mutation). (B) A de novo mutation (thunderbolt) occurring during the gametogenesis in a healthy individual is
transmitted to the offspring (germline mosaicism). (C) Somatic mosaicism resulting from a de novo mutation (thunderbolt) in a
postzygotic cell which is only carried by a fraction of somatic cells. (D) Modulation of gene expression resulting from intragenic intra-
allelic interaction (cis-interaction). (E) Modulation of gene expression resulting from intragenic inter-allelic interaction (trans-interaction).
(F) Modulation of gene expression by a modifier or epistatic gene which can map on the same (left) or another chromosome (right).
(G) Mitochondrial inheritance deriving from random segregation of mitochondria during cell replication. The dashed line represents the
“phenotypic threshold level” for the mutation of mitochondrial DNA to manifest (wild-type mitochondria are blue, mutant mitochondria are
pink). (H) Genomic imprinting through epigenetic mechanisms enables postzygotic cells to retain memory of the parental origin of an
allele. In the example, a mutation in a gene maternally imprinted is not expressed in the offspring when transmitted by the mother.
(I) X-chromosome inactivation leads to functional inactivation of one copy of chromosome X in cells of female individuals to provide
dosage compensation between the sexes. Skewed X-inactivation occurs when the inactivation of one X-chromosome is favored over the
other (wild-type allele is white, mutant allele is black).
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Moreover, the ratio of mutant to wild-type mtDNA copies can
change over time and between tissues, and the threshold for
mutant mtDNA molecules to express into the phenotype is
highly tissue specific. As a result, mutations in mtDNA can have
low penetrance, extremely variable expressivity and pleiotropy,
with rather unpredictable effects on the phenotype. Different
levels of heteroplasmy can explain intrafamilial divergent pheno-
types in mitochondrial DNA disorder.26 Low-level and/or
tissue-limited heteroplasmy may represent major challenges for
clinicogenetic diagnoses. NGS with deep sequence coverage and
extraction of DNA from tissues of interest enhance sensitivity
and allow for accurate quantification of heteroplasmy.13
Epigenetic Factors
Penetrance and expressivity of genetic variants also depend on
the activity status of loci carrying them. Epigenetic modifications
are changes in gene expression which do not entail a change in
DNA sequence and, although being not permanent, can be
mitotically and/or meiotically heritable.73 These include DNA
methylation, histone modification, and non-coding RNA-
associated gene silencing.73 Epigenetic factors are responsible of
genomic imprinting and X-chromosome inactivation, and are
also recognized in disorders whose primary molecular underpin-
ning is either a genetic or chromosomal defect, as in FXS, where
the “full” mutation in FMR1 triggers epigenetic events that
reduce/abolish its transcription.
Genomic Imprinting
Some AD disorders exhibit parent-of-origin effects; namely, the
mutant allele can be transmitted by either parent, the disease
phenotype is usually expressed only when the genetic variant is
inherited from the mother or father.1 The best characterized
phenomenon leading to parent-of-origin effect is genomic
imprinting, that is the silencing of an allele through DNA meth-
ylation depending on the parent of origin (Fig 3H).1 For
instance, the gene encoding ε-sarcoglycan (SGCE) and account-
ing for 1/3 of myoclonus-dystonia is maternally imprinted.17,18
Heterozygous variants in SGCE most often exhibit incomplete
penetrance if they are inherited from the mother. Differential
methylation of CpG dinucleotides in the promoter region of
SGCE has been proven as molecular mechanism.17,18 Individuals
who carry the mutation in the imprinted allele usually do not
manifest symptoms but can transmit it to the offspring, which
results in apparent generation skipping. Intriguingly, in 6% of
individuals with SGCE-related myoclonus-dystonia, the patho-
genic variant is transmitted by the mother.16 The reasons for loss
of the maternal imprinting are unknown, but removal of differ-
entially methylated regions or mutations in regions that are criti-
cal for imprinting regulation may be hypothesized. In these cases,
the phenotype may be milder, thus contributing to intrafamilial
variable expressivity.
X-Chromosome Inactivation
X-chromosome inactivation is the transcriptional silencing of
one X chromosome in female mammalian cells in order to
equalize X-linked gene dosage between females and males.1
X-inactivation is usually a random phenomenon, and females
carrying a genetic variant on chromosome X are in fact mosaic,
with each cell population functionally hemizygous.1 Hence,
female carriers of genetic variants on chromosome X would be
expected to produce approximately half of an abnormal gene
product, thus manifesting milder phenotypes compared to males
carrying the same variant, as often observed in FXTAS, FXS,
and X-linked dystonia-parkinsonism (OMIM# 314250).74,75
However, since X-inactivation occurs in the early stages of
female embryogenesis, there is wide variable expressivity of
X-linked mutant alleles in females. In addition, some X-linked
disorders may have a deleterious effect on cell function during
early embryogenesis, a phenomenon that may lead to extreme
skewing of the distribution of cell populations (Fig 3I). Finally,
some genes escape X-inactivation and are expressed from both
the active and inactive X chromosome. Such genes are potential
contributors to sexually dimorphic traits, to phenotypic variabil-
ity among females heterozygous for X-linked conditions, and to
clinical abnormalities in patients with abnormal X chromosomes.
All these mechanisms contribute to phenotypic heterogeneity in
female carriers of a mutant allele on chromosome X.1
Environmental Factors
The phenotype of some single-gene disorders is also influenced
by environmental factors, including the direct exposure of cells
to harmful or potentially harmful chemicals (eg, dietary compo-
nents), ionizing radiation, and traumas.
The first mechanism is exemplified by inborn errors of metab-
olism, which are due to deficiency of a single enzyme catalyzing
a step in a specific metabolic pathway and manifest with the
introduction of the substrate whose metabolism is defective. A
paradigmatic example is phenylketonuria (OMIM# 261600),
which is caused by biallelic mutations in the gene PAH encoding
the enzyme responsible to convert phenylalanine into tyrosine.
Defective enzymatic activity leads to severe intellectual disability
in the context of a normal diet, whereas an early and relatively
strict phenylalanine-restricted diet results in a healthy phenotype
or in mild neurological impairment.76
Another example of gene–environment interaction which can
influence phenotypic heterogeneity is provided by ataxia-telangi-
ectasia (AT; OMIM# 208900). AT is a rare autosomal recessive
disorder due to mutations in the ATM gene. ATM encodes a
critical regulator of the cellular response to DNA double strand
breaks. Individuals carrying mutations show hypersensitivity to
ionizing radiation and a high incidence of cancer, primarily of
lymphoid origin.77
Finally, in the context of DYT-TOR1A, a positive association
between a history of complications of vaginal delivery and mani-
festation of dystonia was demonstrated, thus suggesting that peri-
natal adversities might modulate penetrance in DYT-TOR1A.15
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Unknown Factors
A significant proportion of incomplete penetrance, variable
expressivity and pleiotropy is not explained by the aforementioned
mechanisms. ATP1A3- and TUBB4-related disorders represent
emblematic examples. ATP1A3 encodes a subunit of the trans-
membrane Na+/K+ ATPase, which is the major contributor to
rapid restoration of neuronal membrane potential after rapid depo-
larization. Monoallelic variants in ATP1A3 have been associated
with a number of neurological disorders, including alternating
hemiplegia of childhood (AHC) type 2 (OMIM# 614820), rapid-
onset dystonia-parkinsonism (RDP; OMIM# 128235), and the
cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineu-
ral hearing loss (CAPOS) syndrome (OMIM# 601338).32 More-
over, EKG dynamic abnormalities have been detected in all
ATP1A3-related syndromes, with a risk of life-threatening cardiac
rhythm abnormalities equivalent to that observed in cardiac
channelopathies.78 Very recently, a distinct neonatal-onset pheno-
type named D-DEMØ has been linked to ATP1A3,
encompassing dystonia, facial dysmorphism, encephalopathy with
developmental delay, brain MRI abnormalities always associated
with cerebellar hypoplasia, but absence of hemiplegia (Ø).79
Mechanisms underlying this wide phenotypic heterogeneity are
controversial. Review of published cases revealed that the same
genetic variant may account for different phenotypes (eg, RDP in
one family, but AHC in another) and that there is a growing num-
ber of patients with intermediate and non-classic phenotypes.
Monoallelic variants in TUBB4A account for hypomyelination
with atrophy of the basal ganglia and cerebellum (H-ABC) syn-
drome (OMIM# 612438), a rare neurodegenerative disorder of
infancy and childhood, and for “hereditary whispering dysphonia”
(formerly DYT4; OMIM# 128101), in which brain imaging is
usually unremarkable.33 Cases with clinical phenotype character-
ized by severe generalized dystonia associated with pyramidal, bul-
bar and cerebellar features, but imaging findings at least partially
consistent with H-ABC syndrome have been reported, so that
genotype–phenotype correlation is controversial.34
Discussion
MD have emerged as paradigmatic example of challenging
genotype–phenotype correlations due to their high degree of
genotypic and phenotypic heterogeneity. This landscape is set to
get even more intriguing with the advent of long-read sequenc-
ing (single molecule real-time sequencing and nanopore
sequencing) and other technologies (eg, electronic nano-device
sequencing, nanochannel genome mapping) which promise to
overcome intrinsic limitations of PCR-based NGS.60 As proof of
the ongoing new revolution in sequencing technology, over few
years, a SINE-VNTR-Alu (SVA) retrotransposon insertion in
TAF1 has been suggested as the possible molecular cause of X-
linked dystonia-parkinsonism, with a hexameric repeat expansion
within the SVA insertion acting as a genetic modifier of disease
expressivity.75,80 Moreover, intronic pentanucleotide repeat
expansions were detected in different genes related to familial
cortical myoclonic tremor syndromes,81 and a trinucleotide
repeat expansion in NOTCH2NLC was linked to neuronal
intranuclear inclusion disease.82 Most of these findings also shed
light to the relatively unexplored non-coding regions of the
genome in the etiopathogenesis of MD and neurodegenerative
diseases.
Some considerations arise from our overview of the phenom-
enological and mechanistic bases of phenotypic heterogeneity in
monogenic disorders, which ultimately fuels the complexity of
clinicogenetic correlations.
First, establishing that a specific genetic variant in a particular
individual with a given disorder is the molecular underpinning
responsible of its phenotype does not allow to automatically infer
that this mutant genotype will invariably lead to the same phe-
notype in all individuals harboring it. This can only be
established (or refuted) empirically by comprehensive, ideally
prospective, analysis of the genotype in question.
Second, determining to what extent genetic test results corre-
late with clinical characteristics will be an increasingly demanding
challenge in the post-NGS era. Indeed, WES and WGS detect
in each individual several thousand and a few million sequence
variants that differ from the human genome reference, respec-
tively. The evaluation of variant pathogenicity (ie, the probabilis-
tic assertion of the likelihood that the variant is disease-causing)
and the integration of genetic findings with the phenotypic fea-
tures and family history of an affected individual are steps of a
complex, multidisciplinary process to establish a genetic diagno-
sis, involving bioinformaticians, geneticists and clinicians. Always
more often MD specialists will be required to formulate chal-
lenging pathogenicity assertions by matching data collected in
the clinical arena with findings from genetic testing.
Understanding the relationship between genotype and pheno-
type is the cornerstone of precision medicine and a must for cli-
nicians in the post-NGS era. Automated processes and machine
learning algorithms have hitherto failed to provide accurate
genotype-to-phenotype prediction, which limits their use in
clinical diagnostics and neurogenetic research. Despite their
expected refinement in the next future, it is likely that they will
never replace the role of clinicians and geneticists entirely, espe-
cially in the MD field, which relies on fine-grained clinical judg-
ment to define phenotypes without parallel in neurology. For all
these reasons, the exponential growth of genetic knowledge
driven by NGS has reaffirmed the central role of meticulous
clinical phenotyping. More specifically, it has promoted
individual-oriented “deep phenotyping”,83 ie, the detailed and
comprehensive analysis of discrete components of a phenotype
that goes beyond what is typically recorded in clinical charts (eg,
nuanced phenotypic traits, such as “short stature” or “mild dys-
morphic features”), generally in a way which is computationally
accessible and enables to integrate the resulting wealth of data
with non-clinical information. In other words, a transition from
the “definition” to the “holistic characterization” of phenotypes
has been started since the NGS era. In clinical practice, deep
phenotyping will further guide clinicians through differential
diagnosis, selection of genetic tests and interpretation of their
results, targeted therapeutic interventions and genetic counseling.
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In the research setting, it will help to expand the knowledge on
established genotype–phenotype correlations or in determining
novel ones.
In conclusion, deep phenotyping, with characterization and
continual updating of “core” phenotypes, and comprehension of
determinants of genotype–phenotype complex relationships are
crucial for clinicogenetic correlations and will have always more
implications for diagnosis, treatment and genetic counseling.
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